🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 805111101 (prev. 00764X202 )
- Market Cap
- Small Cap
- Previous Symbol
- MSTX (changed 4/28/2017)
- Previous Name
- Mast Therapeutics, Inc.
Business: Savara, Inc. clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company has two product candidates in late stage clinical trials including AeroVanc, the first dry powder inhaled antibiotic being developed for the treatment of persistent MRSA infection in people with CF and Molgradex, a proprietary, nebulized formulation of recombinant human GM-CSF for the treatment of PAP.
Notes: April 27, 2017-- Mast Therapeutics, Inc. (NYSE MKT: MSTX) and Savara Inc. have complete a merger today, Thursday, April 27, 2017. Following the merger, Mast Therapeutics, Inc. will have a corporate name and CUSIP change, undergo a 1-70 reverse stock split, and will begin trading on Nasdaq under the ticker symbol SVRA.
Company Contact
- CEO
- Matthew Pauls
- CFO
- David L. Lowrance
- Headquarters
- 6836 Bee Cave Road, Building III, Suite 200, Austin, TX 78746
- Phone
- 512-614-1848
- Investor Relations
- Anne Erickson · 512-851-1366 · anne.erickson@savarapharma.com